Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 12c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.69), $0.12 better than the analyst estimate of ($0.81).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Bristow Group to acquire Berry Aviation for $105 million